Oxymetazoline Hydrochloride Nasal Spray Pharma Grade API is supplied as a white to off-white crystalline powder with pharmacopeial identity confirmed by infrared absorption and liquid chromatographic retention time. The substance is the hydrochloride salt of 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol, CAS 2315-02-8, with molecular formula C16H24N2O·HCl and molecular weight 296.84 g/mol. The salt contributes approximately 11.94% chloride by mass. The product is manufactured under ICH Q7 and is intended primarily for topical nasal-spray presentation at 0.05% w/v. Use in tablet, capsule, granule, oral, and injectable matrices requires formulation-specific data for dose, solubility, content uniformity, and systemic safety.

Grade nomenclature is manufacturer-specific. The certificate of analysis carries the lot number, manufacturing date, retest date, storage condition, and tested specification. Separate grade codes may distinguish micronized nasal-spray material, direct-compression material for solid oral dosage forms, and low-endotoxin material for injectable development. No universal model designation exists across suppliers. The API is released only after identity, assay, related substances, residual solvent, water content, and residue-on-ignition testing is completed. Finished dosage form manufacturing is governed by FDA 21 CFR 210/211 where applicable.

What Identity and Purity Boundaries Are Defined by the Compendial Monograph?

Compendial release for oxymetazoline hydrochloride includes infrared absorption spectrophotometry per USP <197>, chloride identification per USP <221>, and liquid chromatographic retention time against a reference standard. Assay is determined by HPLC per USP <621> and calculated on the anhydrous basis. Related substances are controlled by area percentage with a reporting threshold of 0.05%. Water content is determined by Karl Fischer titration per USP <921> Method Ia. Residue on ignition is measured per USP <281>. The following representative release criteria apply to the nasal-spray grade and are adapted from current pharmacopeial requirements:

Residual solvent control follows USP <467> and ICH Q3C. Methanol, dichloromethane, and acetone are monitored when used in the final synthetic step. Class 2 limits apply to dichloromethane at 600 ppm and methanol at 3000 ppm; acetone is controlled at 5000 ppm if present. Elemental impurities are screened according to USP <232>/<233> and ICH Q3D. Palladium from hydrogenation catalysts is controlled by the permissible daily exposure calculated from the maximum intended daily dose. For injectable development, bacterial endotoxin testing per USP <85> and bioburden testing per USP <61>/<62> are added to the release panel. The API itself is not terminal-sterilized; injectable finished products must be sterilized by a validated terminal or aseptic process.

Particle Engineering and Processability in Tablet, Capsule, and Granule Forms

For solid oral dosage forms, particle size distribution is the dominant process variable. Low-dose tablet blends prepared by direct compression require geometric dilution of the API before main blending because the active dose is small relative to tablet mass. Sieve milling through a 250 µm screen may be used to break agglomerates. Content uniformity is evaluated per USP <905>, and blend uniformity sampling is performed at multiple locations with triplicate samples. If direct compression is used, the API fraction is commonly preblended with a carrier such as spray-dried lactose monohydrate at a 1:10 ratio before addition to the main blender. A twin-shell blender of 300 L to 600 L with an intensifier bar is typical; fill level is maintained at 60% to 70% of nominal volume, and rotation speed is kept below 15 rpm to reduce segregation of fine API. Blend assay RSD acceptance is commonly set at ≤5.0% for development batches.

For capsule filling, a dosator or tamping-pin machine is used with pin height adjusted to achieve target fill weight. Direct filling of neat API is not acceptable because of the low mass per capsule. Dry granulation by roller compaction is preferred over aqueous wet granulation for the hydrochloride salt because moisture can alter flow and water content on the anhydrous basis. Roller compaction with roll pressure in the range of 5 kN/cm to 10 kN/cm is used for low-dose blends, followed by milling to a uniform granule size. Dissolution testing for tablet and capsule prototypes is performed using USP <711> apparatus 2 at 50 rpm in 900 mL of 0.1 N HCl at 37°C, with sampling at 15, 30, 45, and 60 min. No official dissolution monograph exists for oxymetazoline hydrochloride oral products; therefore, in-house acceptance criteria are derived from formulation development data.

When Injectable and Oral Systemic Use Requires Additional Data

Injectable formulations of oxymetazoline hydrochloride are not established in current major pharmacopeias as commercial presentations. Published data for this specific configuration is limited. Any injectable use would require nonclinical and clinical safety data because of systemic alpha-adrenergic activity. The API can be supplied with reduced bioburden and endotoxin control for development, but the final product must meet USP <1> Injections, USP <788> for particulate matter, and USP <85> for endotoxin. Terminal sterilization is formulation-dependent. If the drug substance is thermostable in solution, terminal sterilization by autoclave at 121°C for 15 min may be evaluated. If the molecule degrades, aseptic filtration through a 0.22 µm filter is used, provided the API is fully dissolved and filter compatibility is demonstrated.

Oral systemic use is similarly not a standard route for this molecule. Compounded oral solutions would require pH adjustment and preservative compatibility testing. The low concentration needed to avoid systemic vasoconstriction makes content uniformity and dissolution testing critical. For oral solid dosage forms, the API is handled as a pharmacologically active compound at low concentrations; containment systems such as downflow booths or isolators are used to control operator exposure. The product is not a controlled substance, but it can cause mucosal irritation and should be handled according to the safety data sheet.

Compared with phenylephrine hydrochloride, oxymetazoline hydrochloride is an imidazoline derivative with alpha-adrenergic activity that differs from phenylethylamine derivatives in receptor occupancy and duration. Commercially available intranasal oxymetazoline is formulated at 0.05% w/v, while phenylephrine hydrochloride nasal products are often presented at 1.0% w/v. Regulatory monographs and published clinical data support a 12 h decongestant duration for oxymetazoline, whereas phenylephrine is typically redosed every 4 h. Against xylometazoline hydrochloride, another imidazoline, the dose concentration difference is 0.05% w/v versus 0.1% w/v. Naphazoline hydrochloride is also used at 0.05% w/v but has a shorter duration of action. The differences in concentration and duration affect formulation design because the lower mass of oxymetazoline per spray requires stricter content uniformity and pump-delivered dose control.

The free base is more lipophilic than the hydrochloride salt. The salt form is selected for aqueous nasal spray because it permits solution concentration at 0.05% w/v in buffered vehicles. If the pH of the final formulation is raised above 7.0, free base precipitation may occur. The hydrochloride salt is incompatible with strong bases and strong oxidizing agents. The imidazoline ring is susceptible to degradation under strongly acidic or alkaline conditions; therefore, aqueous granulation and injectable buffer systems must be pH-controlled.

Stability Data Define the Packaging Envelope and Retest Date

Long-term stability data are generated according to ICH Q1A. The API is stored at 20°C to 25°C with excursions permitted to 15°C to 30°C, protected from light. Packaging consists of double low-density polyethylene liners inside a heat-sealed aluminum foil laminate bag, placed in a high-density polyethylene drum. If ambient relative humidity exceeds 60% during dispensing, the product should be equilibrated in a dry room or glovebox because moisture uptake can alter water content and affect flow for direct compression. Photostability is evaluated per ICH Q1B. Oxidative degradation is controlled by nitrogen overlay in packaging. Forced degradation studies under acidic, basic, oxidative, thermal, and photolytic conditions are used to confirm that the HPLC method is stability-indicating.

Batch-to-batch process variability is controlled by setting particle size and bulk density ranges. For low-dose tablets, bulk density below 0.35 g/cm³ or above 0.65 g/cm³ can alter capsule fill weight and tablet weight variability. When the API is micronized for nasal suspension, the specific surface area may exceed 5 m²/g; this increases electrostatic adhesion and requires humidity-controlled handling. If these limits are not met, re-milling or dry granulation may be introduced, but such operations require change control under ICH Q7. The final release specification is therefore not limited to chemical purity; it includes physical attributes that determine performance in downstream unit operations.